Daxor Co. (NASDAQ:DXR) Short Interest Up 7.1% in December

Daxor Co. (NASDAQ:DXR) was the target of a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 9,000 shares, a growth of 7.1% from the December 15th total of 8,400 shares. Based on an average daily trading volume, of 16,800 shares, the days-to-cover ratio is presently 0.5 days. Approximately 0.5% of the company’s stock are short sold.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Daxor stock. Keyes Stange & Wooten Wealth Management LLC lifted its stake in Daxor Co. (NASDAQ:DXR) by 34.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,612 shares of the company’s stock after acquiring an additional 3,771 shares during the period. Keyes Stange & Wooten Wealth Management LLC owned approximately 0.30% of Daxor worth $126,000 at the end of the most recent reporting period. 1.34% of the stock is currently owned by hedge funds and other institutional investors.

Daxor Price Performance

Shares of NASDAQ DXR traded up $0.41 during midday trading on Friday, reaching $8.50. The company’s stock had a trading volume of 1,102 shares, compared to its average volume of 5,653. The firm has a 50 day moving average price of $8.56 and a 200-day moving average price of $8.80. Daxor has a 12-month low of $7.19 and a 12-month high of $10.02.

About Daxor

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.